PCI Biotech (OSE: PCIB) has recently announced a share option scheme for Morten Luhr, the newly appointed Chief Scientific Officer (CSO). This move aligns with the company's long-term growth strategy and offers several benefits for both the new CSO and the company itself. Let's delve into the details of this scheme and its potential impact on PCI Biotech's future.



The share option scheme granted to Morten Luhr consists of 75,000 share options, with a strike price of NOK 1.35, equal to the volume weighted average share price (VWAP) for the last 5 days of trade prior to the grant date. The share options vest annually with 1/3 over a three-year vesting term, with the first 1/3 vesting in Q3 2025 and the vesting term ending in Q3 2027. The share options are subject to service-based vesting conditions and have a value cap of 20 times the strike price. If the value cap threshold is met, all share options will vest immediately and be available for exercise.

This share option scheme offers several advantages for Morten Luhr and PCI Biotech:

1. Alignment with long-term growth strategy: The gradual vesting schedule encourages Morten Luhr to stay with the company for an extended period, aligning his interests with PCI Biotech's long-term success. This helps to ensure that the new CSO is committed to the company's growth and development.
2. Performance-based incentives: The value cap of 20 times the strike price provides an additional incentive for Morten Luhr to perform well and contribute to the company's success. If the share price reaches this threshold, all of his share options will vest immediately, potentially resulting in a significant financial reward.
3. Retention and motivation: The share option scheme serves as a retention tool, encouraging Morten Luhr to remain with PCI Biotech. It also motivates him to work diligently and make valuable contributions to the company, as his financial rewards are directly tied to his performance and the company's success.
4. Attracting and retaining talent: By offering a competitive share option scheme, PCI Biotech can attract and retain top talent in the industry. This helps to ensure that the company has a strong and experienced leadership team, which is crucial for long-term success.

In conclusion, PCI Biotech's share option scheme for Morten Luhr is a strategic move that aligns with the company's long-term growth strategy. The scheme offers several benefits for both the new CSO and the company, including alignment with long-term goals, performance-based incentives, retention and motivation, and attracting and retaining talent. As PCI Biotech continues to grow and develop, this share option scheme will play a crucial role in supporting the company's success.